- Home
- ICLK vs ALXO Comparison
ICLK vs ALXO Comparison
Compare ICLK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLK
- ALXO
- Stock Information
- Founded
- ICLK 2009
- ALXO 2015
- Country
- ICLK Hong Kong
- ALXO United States
- Employees
- ICLK N/A
- ALXO N/A
- Industry
- ICLK Computer Software: Prepackaged Software
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- ICLK Technology
- ALXO Health Care
- Exchange
- ICLK Nasdaq
- ALXO Nasdaq
- Market Cap
- ICLK 70.9M
- ALXO 76.5M
- IPO Year
- ICLK 2017
- ALXO 2020
- Fundamental
- Price
- ICLK $7.70
- ALXO $1.12
- Analyst Decision
- ICLK
- ALXO Buy
- Analyst Count
- ICLK 0
- ALXO 6
- Target Price
- ICLK N/A
- ALXO $6.64
- AVG Volume (30 Days)
- ICLK 57.0K
- ALXO 775.3K
- Earning Date
- ICLK 11-27-2024
- ALXO 03-06-2025
- Dividend Yield
- ICLK N/A
- ALXO N/A
- EPS Growth
- ICLK N/A
- ALXO N/A
- EPS
- ICLK N/A
- ALXO N/A
- Revenue
- ICLK $130,443,999.00
- ALXO N/A
- Revenue This Year
- ICLK $26.49
- ALXO N/A
- Revenue Next Year
- ICLK $12.11
- ALXO N/A
- P/E Ratio
- ICLK N/A
- ALXO N/A
- Revenue Growth
- ICLK N/A
- ALXO N/A
- 52 Week Low
- ICLK $1.03
- ALXO $0.96
- 52 Week High
- ICLK $11.38
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- ICLK 42.86
- ALXO 38.53
- Support Level
- ICLK $7.85
- ALXO $1.00
- Resistance Level
- ICLK $8.26
- ALXO $1.22
- Average True Range (ATR)
- ICLK 0.59
- ALXO 0.09
- MACD
- ICLK -0.14
- ALXO 0.00
- Stochastic Oscillator
- ICLK 14.12
- ALXO 35.12
About ICLK iClick Interactive Asia Group Limited
iClick Interactive Asia Group Ltd is an enterprise and marketing cloud Platform in China. It offers a consumer full lifecycle solution that addresses client's needs from traffic acquisition, customer relations management, and business decision optimization driven by data analytics in the retail era. It has two operating segments: Marketing Solutions, and Enterprise Solutions. Geographically, it derives the majority revenue from Mainland China and also has a presence in Hong Kong and other countries.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.